These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 30987670)

  • 1. Development of a neurocognitive test battery for HIV-associated neurocognitive disorder (HAND) screening: suggested solutions for resource-limited clinical settings.
    Chan LG; Ho MJ; Lin YC; Ong Y; Wong CS
    AIDS Res Ther; 2019 Apr; 16(1):9. PubMed ID: 30987670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of HIV-associated neurocognitive disorder (HAND) in Turkey and assessment of Addenbrooke's Cognitive Examination Revised (ACE-R) test as a screening tool.
    Korten V; Ay U; Harı E; Tigen Tükenmez E; Gencer S; Akça Kalem S; Demirtaş Tatlıdede A; Gürvit İH
    HIV Med; 2021 Jan; 22(1):60-66. PubMed ID: 32964651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Montreal Cognitive Assessment (MoCA) for HIV-Associated Neurocognitive Disorders.
    Rosca EC; Albarqouni L; Simu M
    Neuropsychol Rev; 2019 Sep; 29(3):313-327. PubMed ID: 31440882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is the use of the QPC cognitive complaints questionnaire relevant for the screening strategy of HIV-Associated neurocognitive disorders?
    Zaegel-Faucher O; Laroche H; Tixier M; Morisseau V; Obry-Roguet V; Poizot-Martin I
    AIDS Care; 2021 Mar; 33(3):389-397. PubMed ID: 32279542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive screening in treatment-naïve HIV-infected individuals in Hong Kong - a single center study.
    Chan FCC; Chan P; Chan I; Chan A; Tang THC; Lam W; Fong WC; Lee MP; Li P; Chan GHF
    BMC Infect Dis; 2019 Feb; 19(1):156. PubMed ID: 30760220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychometric utility of the international HIV dementia scale and Montreal Cognitive Assessment in HIV-associated asymptomatic neurocognitive impairment.
    Aita SL; Kaewpoowat Q; Yasri S; Rerkasem A; Rerkasem K; Choovuthayakorn J; Ausayakhun S; Robertson K; Roth RM; Robbins NM
    J Neurovirol; 2021 Aug; 27(4):568-578. PubMed ID: 34185242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuropsychological tests associated with symptomatic HIV-associated neurocognitive disorder (HAND) in a cohort of older adults in Tanzania.
    Fotheringham L; Lawson RA; Urasa S; Boshe J; Mukaetova-Ladinska EB; Rogathi J; Howlett W; Dekker MCJ; Gray WK; Evans J; Walker RW; Makupa PC; Paddick SM
    J Int Neuropsychol Soc; 2024 Aug; 30(7):660-670. PubMed ID: 38766814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for HIV-associated neurocognitive disorders in perinatally infected adolescents: youth-International HIV Dementia Scale validation.
    Phillips NJ; Thomas KGF; Myer L; Sacktor N; Zar HJ; Stein DJ; Hoare J
    AIDS; 2019 Apr; 33(5):815-824. PubMed ID: 30649059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Test Accuracy of the Montreal Cognitive Assessment in Screening for Early Poststroke Neurocognitive Disorder: The Nor-COAST Study.
    Munthe-Kaas R; Aam S; Saltvedt I; Wyller TB; Pendlebury ST; Lydersen S; Ihle-Hansen H
    Stroke; 2021 Jan; 52(1):317-320. PubMed ID: 33250039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for neurocognitive impairment in HIV-positive adults aged 50 years and older: Montreal Cognitive Assessment relates to self-reported and clinician-rated everyday functioning.
    Fazeli PL; Casaletto KB; Paolillo E; Moore RC; Moore DJ; The Hnrp Group
    J Clin Exp Neuropsychol; 2017 Nov; 39(9):842-853. PubMed ID: 28122474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for HIV-Associated Neurocognitive Disorders: Sensitivity and Specificity.
    Robbins RN; Scott TM; Gouse H; Marcotte TD; Rourke SB
    Curr Top Behav Neurosci; 2021; 50():429-478. PubMed ID: 32677005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determining optimal impairment rating methodology for a new HIV-associated neurocognitive disorder screening procedure.
    Kamminga J; Bloch M; Vincent T; Carberry A; Brew BJ; Cysique LA
    J Clin Exp Neuropsychol; 2017 Oct; 39(8):753-767. PubMed ID: 28052738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Repeatable Battery for the Assessment of Neuropsychological Status as a screening strategy for HIV-Associated Neurocognitive Disorders.
    Costaggiu D; Pinna E; Serchisu L; Barcellona D; Piano P; Ortu F; Marongiu F; Mandas A
    AIDS Care; 2021 Mar; 33(3):357-363. PubMed ID: 32183560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Montreal Cognitive Assessment-Basic (MoCA-B) is not a reliable screening tool for cognitive decline in HIV patients receiving combination antiretroviral therapy in rural South Africa.
    Hakkers CS; Beunders AJM; Ensing MHM; Barth RE; Boelema S; Devillé WLJ; Tempelman HA; Coutinho RA; Hoepelman AIM; Arends JE; van Zandvoort MJE
    Int J Infect Dis; 2018 Feb; 67():36-40. PubMed ID: 29183843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A brief and feasible paper-based method to screen for neurocognitive impairment in HIV-infected patients: the NEU screen.
    Muñoz-Moreno JA; Prats A; Pérez-Álvarez N; Fumaz CR; Garolera M; Doval E; Negredo E; Ferrer MJ; Clotet B;
    J Acquir Immune Defic Syndr; 2013 Aug; 63(5):585-92. PubMed ID: 24135776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of Using the Montreal Cognitive Assessment (MoCA) as a Screening Tool for HIV-Associated Neurocognitive Disorders (HAND) In Multi-Ethnic Malaysia.
    Mukherjee T; Sakthivel R; Fong HY; McStea M; Chong ML; Omar SF; Chin AV; Kamaruzzaman S; Kamarulzaman A; Rajasuriar R; Cysique LA
    AIDS Behav; 2018 Oct; 22(10):3226-3233. PubMed ID: 29508103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurocognitive Impairment in the Combined Antiretroviral Therapy Era in a Romanian Cohort of Young Adults with Chronic HIV Infection.
    Temereanca A; Ene L; Rosca A; Diaconu CC; Luca A; Burlacu R; Radoi R; Bulacu-Talnariu A; Marcotte TD; Achim CL; Ruta S
    AIDS Res Hum Retroviruses; 2020 May; 36(5):367-372. PubMed ID: 31476875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Alzheimer's disease-8 and Montreal Cognitive Assessment as screening tools for neurocognitive impairment in HIV-infected persons.
    Overton ET; Azad TD; Parker N; Demarco Shaw D; Frain J; Spitz T; Westerhaus E; Paul R; Clifford DB; Ances BM
    J Neurovirol; 2013 Feb; 19(1):109-16. PubMed ID: 23345074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validity of the International HIV Dementia Scale in South Africa.
    Joska JA; Westgarth-Taylor J; Hoare J; Thomas KG; Paul R; Myer L; Stein DJ
    AIDS Patient Care STDS; 2011 Feb; 25(2):95-101. PubMed ID: 21214343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of the Montreal Cognitive Assessment (MoCA) and its subset in HIV-associated neurocognitive disorder (HAND) screening.
    Kim WJ; Ku NS; Lee YJ; Ahn JY; Kim SB; Ahn HW; Hong KW; Song JY; Cheong HJ; Kim WJ; Kim JM; Namkoong K; Choi JY; Kim E
    J Psychosom Res; 2016 Jan; 80():53-7. PubMed ID: 26721548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.